‘I Thought I Had This Thing Beat’: A Story of Relapse and Recovery

January 17, 2018 | Jennifer Mattson

In the summer of 2015, Mollie Warner was living a happy, active life in Rancho Cucamonga, California, with her husband. She worked out regularly at the gym, lifted weights and was even taking a kickboxing class when she started feeling fatigued.

Continue Reading

Inside the Lab: Preventing breast cancer from invading the brain

July 24, 2017 | Denise Heady

A study led by City of Hope neurosurgeon and scientist Rahul Jandial, M.D., Ph.D., offers novel insights on how cancer cells in HER2-positive breast cancer develop the ability to break through the blood-brain barrier and, ultimately, how they can be stopped.

CAR T cells: ‘Soldiers of the Immune System’

July 10, 2017 | Stephanie Smith

T cells were genetically modified in a lab by City of Hope researchers and trained to target specific receptors on patients’ brain tumors - part of an emerging approach to cancer care called immunotherapy.

Inside CAR T Cell Glioblastoma Surgery

January 4, 2017 | Stephanie Smith

Sketches of a brain surgery performed on B., one of several patients in a breakthrough clinical trial for brain cancer at City of Hope. Early results of the trial — describing promising results using CAR T cells for a 50-year-old patient with an aggressive brain cancer called glioblastoma multiforme — were published recently in the New England Journal of Medicine.

Brain cancer 2016: Using CAR T cell therapy to fight tumors

December 28, 2015 | Denise Heady

Patients have long needed a better treatment option for brain tumors. As we enter 2016, just such an option is taking shape: CAR T cell therapy.

New funding for CAR T cell study gives brain cancer research a boost

October 26, 2015 | City of Hope

Brain cancer is one of the toughest foes a doctor can face. It’s a tenacious form of cancer, inoperable in some cases and lethal in many. But at City of Hope, researchers are exploring new ways to conquer the most serious types of brain tumors in a clinical trial that deploys a patient’s own modified T cells to target cancer at the tumor site.